HCID 178418361, compound → HCID 178452211, compound

Participants

Reaction Steps

A suspension of 540 mg of 4-{6-fluoro-2-[4-nitro-1-(tetrahydropyran-2-yl)-1H-pyrazol-3-yl]-3H-benzimidazol-5-yl}piperazine-1-carboxylic acid tert-butyl ester in 15 mL of methanol and 54 mg of palladium-on-charcoal is hydrogenated under 1 bar of hydrogen pressure at ambient temperature for 16 hours. The reaction medium is filtered through celite and the filtrate is concentrated under reduced pressure in a rotary evaporator. 900 mg of 4-{2-[4-amino-1-(tetrahydropyran-2-yl)-1H-pyrazol-3-yl]-6-fluoro-3H-benzimidazol-5-yl}piperazine-1-carboxylic acid tert-butyl ester are obtained in the form of a black solid. 1H NMR (400 MHz, DMSO-d6, δ in ppm): from 1.30 to 2.20 (m, 6H); 1.42 (s, 9H); 3.00 (m, 4H); 3.52 (m, 4H); 3.67 (m, 1H); 3.96 (m, 1H); 5.55 (broad d, J=10.0 Hz, 1H); 7.22 (d, J=7.5 Hz, 1H); 7.46 (d, J=12.5 Hz, 1H); 8.17 (s, 1H). ES mass spectrum: m/z=486 MH+ (base peak).

Provenance & Evidence